Kirk Wilson

This conversation is closed.

To save $$, use genetic testing to discern which diagnostic tests should be done and on whom and which therapies should be used and on whom.

Insurance and Medicare/Medicaid does not pay for genetic testing to conclude the basic genetic predisposition of beneficiaries, its future medical service recipients. If testing were routine routine preventative diagnostic tests could be focused on those with predisposition and done less often on those without a family history and predisposition, saving many more dollars than the one time cost of the tests. Same is true of pharmaceutical therapies, such as statins. Why prescribe expensive statins for an individual with no family history of heart disease, a calcium score of zero, and a negative Kif6 genetic test. It is a waste of money, even if that individual has an unacceptably high cholesterol level. Disclaimer...I have no interest in or stock position in any genetic testing company.

  • thumb
    Mar 5 2011: Some will argue about whom should be privy to the results of such genetic tests. The answer is easy; of course , the test subject, the patient should know the results and receive careful interpretation of the data so it is not misinterpreted or misused; but also so should the party paying for the test know the results, even if it is the person's insurance provider. With the new requirement that all must have insurance and no one can be denied insurance, the debate about who should have access to the information is less problematical.